Oragenics, Inc. OGEN
Set alert
At close · Oct 30
After hours · Oct 30, 4:02 PM ET
- YTD
- -52.05%
- 1 year
- -69.59%
- Open
- 0.3727
- Prev close
- 0.3742
- Mkt cap
- 1.69M
- Vol
- 9.21K
- Avg vol
- 29.24K
- EPS
- -2.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3711
- High
- 0.3855
- Forward P/E
- -0.03
- Beta
- 0.48
- Short ratio
- 0.43
- Inst. own
- 11.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.3272
- 200-d avg
- 0.981
- 1y target
- 0.00
5D chart
Signals (34)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 4:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:55 AM | 4 days ago |
| RSI: Oversold | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 23, 9:35 AM | 1 week ago |
| SMA: Bearish | Oct 22, 2:35 PM | 1 week ago |
| SMA: Bullish | Oct 22, 1:35 PM | 1 week ago |
News
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
1 month ago globenewswire.com
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the…
-
2 months ago benzinga.com
Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its…
2 months ago globenewswire.com
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary…
2 months ago defenseworld.net
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day…
3 months ago globenewswire.com
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital…
5 months ago globenewswire.com
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics,…
5 months ago globenewswire.com
ORAGENICS PROVIDES INVESTOR UPDATE
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has…
-
5 months ago benzinga.com
Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.
-
5 months ago benzinga.com
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San…
5 months ago globenewswire.com
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and…
5 months ago globenewswire.com
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…
-
6 months ago benzinga.com
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a…
6 months ago globenewswire.com
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla. , April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:…
-
6 months ago benzinga.com
Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
6 months ago globenewswire.com
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…
7 months ago defenseworld.net
Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 39.0%
Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling…
7 months ago globenewswire.com
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal…
-
7 months ago benzinga.com
Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has…
7 months ago globenewswire.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering…
-
7 months ago benzinga.com
Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is…
7 months ago globenewswire.com
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal…
-
7 months ago benzinga.com
Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has…
7 months ago globenewswire.com
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent…
8 months ago defenseworld.net
Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) fell 0.3% during mid-day trading on Tuesday. The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded…
-
8 months ago benzinga.com
Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI
Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its…
8 months ago globenewswire.com
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in…
-
9 months ago benzinga.com
Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design
Oragenics, Inc. (NYSE American: OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced it has engaged…
9 months ago globenewswire.com
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
9 months ago benzinga.com
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
Reported November 7, 2025: Oragenics Q3 EPS $(1.96) Up From $(11.32) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(1.96) per share. This is a 82.69 percent increase over losses of $(11.32) per share from the same period last year.
-
1 year ago benzinga.com
Oragenics Regains Nasdaq Compliance
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has…
-
1 year ago benzinga.com
Oragenics Selects Southern Star Research As Clinical Research Organization For Upcoming Phase IIa Clinical Trial Of ONP-002, Lead Drug Candidate For Concussion
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its…
-
1 year ago benzinga.com
Oragenics Enters Manufacturing Agreement With Sterling Pharma For GMP Production Of Concussion Drug, ONP-002
Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
1 year ago benzinga.com
US Stocks Mixed; Dow Gains Over 50 Points
US Stocks Mixed; Dow Gains Over 50 Points
-
1 year ago benzinga.com
Oragenics Prices Public Offering Of Up To $20M Of Preferred Stock And Warrants
Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
1 year ago benzinga.com
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session